RecruitingNCT06184464
Prostatic Size Reduction Following of Leuprorelin Acetate
Prostatic Size Reduction Following the Administration of Leuprorelin Acetate in Localized Prostate Cancer Prior to Radiation Therapy. Pilot Study.
Sponsor
Consorci Sanitari de Terrassa
Enrollment
40 participants
Start Date
Feb 2, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
To determine the possible reduction in prostate size following the administration of Leuprelin prior to the application of radiotherapy.
Eligibility
Sex: MALEMin Age: 18 YearsMax Age: 95 Years
Inclusion Criteria1
- Man with Prostate positive biopsy. Able to Ssgned informed consent form. Need of hormonal treatment before start of radiotherapy
Exclusion Criteria2
- Patients With prostate size of less than 20 cc at diagnosis. Patients With Positive lymph nodes or metastatic prostate cancer disease on imaging studies.
- Patients with Previous pelvic radiation therapy.
Interventions
OTHERACETATE LEUPRELINE
USE ACETATE LEUPRELINE BEFORE AND AFTER PROSTATE DELIMITATION
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06184464
Related Trials
Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial
NCT060228225 locations
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
NCT073320007 locations
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
NCT056166501 location
Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial
NCT070253691 location
Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)
NCT066543363 locations